Cinctive Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-48,855
Closed -$878K – 551
2026
Q2
$878K Buy
+48,855
New +$924K 0.03% 333
2024
Q3
– Sell
-29,129
Closed -$4.6M – 508
2024
Q2
$4.6M Sell
29,129
-49,231
-63% -$6.32M 0.22% 158
2024
Q1
$10.1M Buy
+78,360
New +$9.6M 0.47% 63
2022
Q1
– Sell
-13,300
Closed -$1.2M – 650
2021
Q4
$1.2M Buy
+13,300
New +$1.14M 0.05% 380

Other funds holding SRPT

Cinctive Capital Management's SRPT Position: Q3 2026 in Review

Cinctive Capital Management sold out of Sarepta Therapeutics (SRPT) in Q3 2026, closing a stake of 48,855 shares — an estimated $878K sold.

Cinctive Capital Management first reported a position in SRPT in Q4 2021 and held it in 4 quarters. The position peaked at $10.1M in Q1 2024. 256 funds tracked by Wall St. Rank hold SRPT as of Q3 2026.

  • Cinctive Capital Management reported no remaining Sarepta Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Cinctive Capital Management sold 48,855 Sarepta Therapeutics shares in Q3 2026, an estimated $878K.
  • Cinctive Capital Management first reported a position in Sarepta Therapeutics in Q4 2021 and held it in 4 quarters.
  • Cinctive Capital Management's Sarepta Therapeutics position peaked at $10.1M in Q1 2024.
  • 256 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2026.

Based on Cinctive Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.